Aurinia Pharmaceuticals Inc. (AUPH) stock
AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3058% below fair value
$15.40−0.08 (-0.52%)
Close on Nov 17, 2026Market cap $2.06BP/E 6.7Yield –
Aurinia Pharmaceuticals pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Aurinia Pharmaceuticals's pe ratio was 7.1× on Nov 11, 2026, against 28.8× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 7.1× | −21.4 |
| 2025 | Dec 31, 2025 | 28.5× | – |
See a number that looks wrong?